Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flotetuzumab in advanced CD123-positive hematological malignancies
NCT03739606Phase 2Withdrawn
- Sponsor
- City of Hope
- Start
- Oct 2020
- Primary completion
- Oct 2020
01
Overview
Phase 2, open-label, single-arm trial of flotetuzumab in acute lymphoblastic leukemia (ALL), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), chronic myelogenous leukemia (CML) and 4 more, sponsored by City of Hope. Primary endpoint: Complete Remission Rate at 112 days. Planned start Oct 2020; status: withdrawn.
02
Drugs
flotetuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)chronic myelogenous leukemia (CML)hairy cell leukemia (HCL)systemic mastocytosis (SM)
Beyond the preview
Go deeper on NCT03739606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739606.